Biomednewsbreaks - Longeveron Inc. (NASDAQ: LGVN) Elected New Board Member At Annual Stockholder Meeting

(MENAFN- Investor Brand Network) Longeveron (NASDAQ: LGVN) , a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, including
hypoplastic left heart syndrome (“HLHS”)
and
Alzheimer's disease, is announcing an addition to its board of directors. According to the announcement, senior healthcare investment banker Neha Motwani was elected to the board during the company's recent Annual Meeting of Stockholders. Motwani brings more than two decades of experience to her new role as board member. Most recently she was managing director of healthcare investment banking at William Blair; she has also held a variety of roles at Truist Securities, Oppenheimer and Company, Stifel Financial, and Cowen and Company.“I am delighted to welcome Neha, with her tremendous healthcare industry experience, to the board of directors,” said Longeveron cofounder, chief science officer and board chair
Joshua Hare
in the press release.“Her extensive knowledge of biopharma company operations, financing and capital markets will bring significant value to Longeveron as we continue to advance
Lomecel-B(TM), our proprietary, scalable, allogeneic cellular therapy. With five positive clinical trials across three indications, we believe Lomecel-B
has the potential to be an important therapy for some of the most difficult diseases and conditions associated with aging.”

To view the full press release, visit

About Longeveron Inc.

Longeveron is a clinical-stage, biotechnology company developing regenerative medicines to address unmet medical needs. The company's lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B(TM) has multiple potential mechanisms of action encompassing provascular, proregenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer's disease and Aging-Related Frailty. The Lomecel-B
HLHS program has received three distinct and important FDA designations: Orphan Drug designation, Fast Track designation and Rare Pediatric Disease designation. To learn more about the company, visit .

NOTE TO INVESTORS:
The latest news and updates relating to LGVN are available in the company's newsroom at

About BioMedWire

BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer

BioMedWire
San Francisco, CA

415.949.5050 Office
...

BioMedWire is powered by IBN

MENAFN10072024000224011066ID1108428381